Aquestive Therapeutics (NASDAQ:AQST) Earns Outperform Rating from Analysts at Oppenheimer

Analysts at Oppenheimer started coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note issued to investors on Monday, June 2nd, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $7.00 price target on the stock. Oppenheimer’s price objective would indicate a potential upside of 91.52% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on AQST. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a report on Friday, March 7th. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Lake Street Capital reduced their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.14.

Aquestive Therapeutics Stock Up 2.7%

Aquestive Therapeutics stock traded up $0.10 during mid-day trading on Monday, hitting $3.66. 703,436 shares of the company’s stock were exchanged, compared to its average volume of 1,533,844. The company’s 50 day simple moving average is $2.69 and its 200-day simple moving average is $3.12. The firm has a market capitalization of $363.04 million, a P/E ratio of -8.10 and a beta of 1.94. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. Research analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Aquestive Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock valued at $15,474,000 after acquiring an additional 82,958 shares during the period. Pale Fire Capital SE lifted its holdings in Aquestive Therapeutics by 154.1% during the first quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company’s stock valued at $3,873,000 after purchasing an additional 809,928 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Aquestive Therapeutics by 7.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company’s stock worth $3,073,000 after acquiring an additional 75,275 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after acquiring an additional 621,614 shares during the period. Finally, Northern Trust Corp grew its position in shares of Aquestive Therapeutics by 3.1% in the fourth quarter. Northern Trust Corp now owns 599,812 shares of the company’s stock valued at $2,135,000 after purchasing an additional 18,199 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.